Lindahl has advised Eurocine Vaccines in negotiating and executing a research collaboration and license agreement with Spixia Biotechnology for the development and commercialization of Chlamydia vaccines. Under the agreement, Eurocine Vaccines receives an exclusive right to develop, manufacture and commercialize vaccine candidates against Chlamydia based on vaccine antigens that Spixia Biotechnology has developed.
Chlamydia is a sexually transmitted bacterial disease for which there are no preventive vaccines on the market today.
Eurocine Vaccines is publicly listed pharmaceutical company that develops vaccines in collaboration with other companies in the industry. Spixia Biotechnology is active within bio technical research and development, in particular within preventive vaccines against Chlamydia.
The Lindahl team consisted of Hugo Norlén (responsible partner), Erika Svensson och Emelie Carmhagen Wernoff.
More information available here (in Swedish).
